[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-hepatic-porphyria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-hepatic-porphyria":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100430348",false,"NCT04883905","ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)","ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)","ELEVATE","Inclusion Criteria:\n\n* Documented diagnosis of AHP, per physician's determination\n\nExclusion Criteria:\n\n* Currently enrolled in a clinical trial for any investigational agent","ALL","12 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.",[24],"Acute Hepatic Porphyria",[26,27,28],"Givosiran","AHP","Acute hepatic porphyria","RECRUITING","2026-04-23",{"date":32,"type":33},"2026-04-27","ACTUAL",{"date":35,"type":33},"2021-04-26",{"date":37,"type":20},"2027-04-01",{"name":39,"class":40},"Alnylam Pharmaceuticals","INDUSTRY",30,""]